Scarica l'app Stockscreener
0.7588
3.82%
0.0279
Dopo l'orario di chiusura:
.71
-0.0488
-6.43%
Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie
Pullback Watch: Can COOP stock double in the next yearMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Aug Big Picture: What hedge funds are buying Lexaria Bioscience CorpEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Leaders: Can Lexaria Bioscience Corp ride the EV waveWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-01-15 23:22:36 - baoquankhu1.vn
Levels Update: What are Lexaria Bioscience Corp. Equity Warrant’s earnings expectationsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView — Track All Markets
Institution Moves: Is Lexaria Bioscience Corp stock a bargain at current levels2025 Valuation Update & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital - TipRanks
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with Dehyd - GuruFocus
Lexaria Releases Annual Letter from the CEO - Investing News Network
Lexaria Bioscience CEO Releases Annual Letter, Outlook for 2026 - Intellectia AI
Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone - MSN
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Will Lexaria Bioscience Corp. Equity Warrant stock maintain dividend yieldJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is Lexaria Bioscience Corp. Equity Warrant stock dividend yield sustainableJuly 2025 Action & Expert Approved Momentum Trade Ideas - Улправда
Why Lexaria Bioscience Corp. stock is seen as undervaluedTrade Analysis Summary & Community Supported Trade Ideas - ulpravda.ru
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higherJuly 2025 Fed Impact & Safe Capital Growth Stock Tips - Улправда
Why Lexaria Bioscience Corp. Equity Warrant stock could be next big winnerJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - Улправда
San Gabriel Valley Tribune - FinancialContent
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
4.73%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):